Company Profile

Articulate Biosciences LLC (AKA: Ionic Pharmaceuticals)
Profile last edited on: 8/24/21      CAGE: 7HTZ2      UEI: EH4LG39HHLQ3

Business Identifier: Injectable viscoelastic gels: treatment of arthritis and other soft tissue disease
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

110 Canal Street 4th Floor
Lowell, MA 01852
Location: Single
Congr. District: 03
County: Middlesex

Public Profile

Currently housed in the Massachusetts Medical Device Development Center (M2D2) Incubator (a JLab facility) in Lowell MA, Articulate Biosciences LLC, is a Boston University spin-out structured around developing injectable viscoelastic gels designed for the treatment of arthritis and other soft tissue diseases. The company's gel utilizes tissue-protecting and function-restoring biomedical polymers designed to help in eliminating chronic joint pain - enabling patients suffering from osteoarthritis to get relieve from pain and restore mobility. Completely different from existing supplements, the firm's synthetic, non-hyaluronic-acid polymer is designed to last significantly longer within the joint than previously available products. Designated Ultravisc, the product injects viscous fluids into osteoarthritic joints - an injectable medical device that resides within the joints for six months as the product lubricates, cushions, and protects the damaged area.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NSF $224,945
Project Title: Bioinert Viscoelastic Gels as Diseased Soft Tissue Lubricants
2017 1 NIH $196,886
Project Title: Long-lasting, Biomimetic Lubricants for Diseased Tissue

Key People / Management

  Benjamin G Cooper -- CEO and Co-founder

  Mark W Grinstaff -- Co-founder:Translational research, polymer & materials science

  Yiannis Monovoukas -- Business, management, product development

  Michel Christopher Wathier

Company News

There are no news available.